Literature DB >> 7508383

Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes.

I Cenci Di Bello1, B Poulain, C C Shone, L Tauc, J O Dolly.   

Abstract

mAbs were produced in mice against highly purified, renatured light chain (LC) of botulinum neurotoxin A (BoNT A) that was immobilised on nitrocellulose to avoid the undesirable use of toxoids. Subcutaneous implants of relatively high amounts (up to 10 micrograms each) of LC allowed its slow release into the systemic circulation and, thus, yielded much higher antibody titres against the underivatized antigen than had hitherto been obtained by conventional immunization. Seven stable hybridoma cell lines were established which secrete mAb of IgG1 and IgG2b subclasses reactive specifically with BoNT A and LC, in native and denatured states, without showing any cross-reactivity with types B, E, F or tetanus toxin. The pronounced reactivities of three mAbs towards refolded LC or intact toxin, observed in immunobinding and precipitation assays, relative to that seen in Western blots imply a preference for conformational epitopes. Though mAbs 4, 5 and 7 failed to neutralize the lethality of BoNT in vivo, administration intraneurally of mAb7 prevented the inhibition of transmitter release normally induced by subsequent extracellular administration of BoNT A. Notably, the latter mAb reacted with a synthetic peptide corresponding to amino acids 28-53 in the N-terminus of the LC, a highly conserved region in Clostridial neurotoxins reported to be essential for maintaining the tertiary structure of the chain. Most importantly, when mAbs 4 or 7 were microinjected inside ganglionic neurons of Aplysia, each reversed, though transiently, the blockade of acetylcholine release by the toxin; this novel finding is discussed in relation to the nature of the zinc-dependent protease activity of the toxin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508383     DOI: 10.1111/j.1432-1033.1994.tb19926.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

2.  Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.

Authors:  M Z Atassi; B Z Dolimbek; M Hayakari; J L Middlebrook; B Whitney; M Oshima
Journal:  J Protein Chem       Date:  1996-10

Review 3.  Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.

Authors:  Laura M Zarebski; Kerrie Vaughan; John Sidney; Bjoern Peters; Howard Grey; Kim D Janda; Arturo Casadevall; Alessandro Sette
Journal:  Expert Rev Vaccines       Date:  2008-02       Impact factor: 5.217

Review 4.  Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells.

Authors:  Michel R Popoff; Bernard Poulain
Journal:  Toxins (Basel)       Date:  2010-04-15       Impact factor: 4.546

Review 5.  Botulinum neurotoxins and botulism: a novel therapeutic approach.

Authors:  Jeeraphong Thanongsaksrikul; Wanpen Chaicumpa
Journal:  Toxins (Basel)       Date:  2011-05-13       Impact factor: 4.546

Review 6.  Monoclonal antibodies and toxins--a perspective on function and isotype.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Toxins (Basel)       Date:  2012-06-11       Impact factor: 4.546

Review 7.  Passive antibody administration (immediate immunity) as a specific defense against biological weapons.

Authors:  Arturo Casadevall
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

8.  Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.

Authors:  Suzanne R Kalb; Jianlong Lou; Consuelo Garcia-Rodriguez; Isin N Geren; Theresa J Smith; Hercules Moura; James D Marks; Leonard A Smith; James L Pirkle; John R Barr
Journal:  PLoS One       Date:  2009-04-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.